Optimal use of recombinant granulocyte colony-stimulating factor with chemotherapy for solid tumors

Danova, Marco; Barni, Sandro; Mastro, Lucia Del; Danesi, Romano; Pappagallo, Giovanni

doi:10.1586/era.11.72

Cited by 10 publications

(5 citation statements)

References 81 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, irradiated hematopoietic cells exhibit a decreased proliferative response toward cytokines. Furthermore, multiple cytokines must be administered to promote the recovery of hematopoiesis, increasing the risk of adverse events and the patients’ financial burden [3,4]. Seeking an efficacious irradiation-resistance agent that promotes hematopoiesis with less severe adverse events could greatly improve the therapeutic efficacy of radiation treatment for malignant carcinoma patients.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Scorpion venom peptide SPVII promotes irradiated cells proliferation and increases the expression of the IL-3 receptor

et al. 2013

View full text Add to dashboard Cite

BackgroundThe previous investigation demonstrated the radioprotective efficacy of peptides isolated from the venom of Buthus Martti Karsch. In this study, the effect of isolated scorpion venom peptide II (SVPII) on irradiated M-NFS-60 cells and mouse bone marrow mononuclear cells (BM-MNCs) was observed. The AlamarBlue cell viability assay, a colony-forming unit (CFU) assay, flow cytometry (FCM), immunofluorescence, and Western blotting were used to evaluate cell proliferation, cell cycle progression, and the expression of the IL-3 receptor (IL-3R) protein in non-irradiated and irradiated cells.ResultsProliferation of irradiated M-NFS-60 cells was significantly accelerated by SPVII, and this effect was further enhanced by co-application of IL-3. Similarly, SPVII increased the number of BM-MNC CFUs and this proliferative effect was greater in the presence of SVPII plus IL-3. In addition, SPVII significantly altered cell cycle progression; SVPII enhanced the fraction of unirradiated M-NFS-60 cells in S phase and the fraction of irradiated M-NFS-60 cells arrested in G2/M. The expression of IL-3R protein by unirradiated M-NFS-60 cells was enhanced significantly by SVPII, and SVPII-induced IL-3R overexpression was 10-fold greater in irradiated M-NFS-60 cells.ConclusionsThese results indicated the hematopoietic growth factor (HGF)-like effects of SVPII on irradiated cells, possibly mediated by upregulation of IL-3R.

show abstract

Section: Discussionmentioning

confidence: 99%

“…The most common drugs used to reverse hematopoietic suppression are colony stimulating factors (CFSs), including granulocyte CSF (G-CSF), granulocyte-macrophage CSF (GM-CSF) [2], and monocyte-macrophage CSF (M-CSF). However, the efficacy of these CSFs is limited and cytokine treatment also causes additional adverse events [3,4]. …”

Section: Introductionmentioning

confidence: 99%

Scorpion venom peptide SPVII promotes irradiated cells proliferation and increases the expression of the IL-3 receptor

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Individuals vote privately on the priority of ideas, and the group decision is made based on these ratings. This technique can be used with non-homogeneous groups (eg, groups including specialists from different areas), and it is especially suitable when achieving a consensus appears particularly difficult 17,18…”

Section: Methodsmentioning

confidence: 99%

“…This paper presents the results of a series of consensus meetings held to clarify the role of mCHT, and oral vinorelbine in particular, in the management of advanced breast cancer. To this end, the nominal group technique (NGT) was applied, consistent with previous studies in the oncology setting 17–20. A summarizing meeting was planned using the Consensus Development Conference Technique 21…”

Section: Introductionmentioning

confidence: 99%

<p>Treating advanced breast cancer with metronomic chemotherapy: what is known, what is new and what is the future?</p>

Cazzaniga¹,

Biganzoli²,

Cortesi³

et al. 2019

OTT

View full text Add to dashboard Cite

The prognosis for patients with locally advanced or metastatic breast cancer (mBC) remains poor, with a median survival of 2–4 years. About 10% of newly diagnosed breast cancer patients present with metastatic disease, and 30%–50% of those diagnosed at earlier stages will subsequently progress to mBC. In terms of ongoing management for advanced/metastatic breast cancer after failure of hormonal therapy, there is a high medical need for new treatment options that prolong the interval to the start of intensive cytotoxic therapy, which is often associated with potentially serious side effects and reduced quality of life. Oral chemotherapeutic agents such as capecitabine and vinorelbine have demonstrated efficacy in patients with mBC, with prolonged disease control and good tolerability. Use of oral chemotherapy reduces the time and cost associated with treatment and is often more acceptable to patients than intravenous drug delivery. Metronomic administration of oral chemotherapy is therefore a promising treatment strategy for some patients with mBC and inhibits tumor progression via multiple mechanisms of action. Ongoing clinical trials are investigating metronomic chemotherapy regimens as a strategy to prolong disease control with favorable tolerability. This article provides an overview of metronomic chemotherapy treatment options in mBC, with perspectives on this therapy from a panel of experts.

show abstract

“…If PEG‐rhG‐CSF is administered only 24 h after EP treatment, cisplatin will still be present in the blood. This could potentially compromise the production of myeloid progenitor cells induced by PEG‐rhG‐CSF, 5 eventually rendering the treatment ineffective 2,6–8 . On the other hand, other studies argue that when cisplatin is infused into the blood, it binds rapidly to plasma proteins 20 .…”

Section: Introductionmentioning

confidence: 99%

Safety and efficacy of administering reduced doses of pegylated recombinant human granulocyte‐colony stimulating factors in patients treated with cisplatin and etoposide for small cell carcinoma: A retrospective study

et al. 2021

View full text Add to dashboard Cite

Background The aim of this study was to discuss the safety and efficacy of administering reduced doses (3 mg) of pegylated recombinant human granulocyte‐colony stimulating factor (PEG‐rhG‐CSF) at approximately 24 h or up to three days following treatment with etoposide and cisplatin (EP). Methods A total of 104 cycles from 31 patients were divided into a PEG‐rhG‐CSF prophylaxis group (PP‐Group) and a control group (No‐PP‐Group). The PP‐Group received a reduced dose of 3 mg of PEG‐rhG‐CSF within a minimum of 15 h and a maximum of 72 h following EP chemotherapy, while the rest did not receive any G‐CSF prophylaxis (No‐PP‐Group). For both groups, complete blood counts, incidence of febrile neutropenia (FN), grade III or IV neutropenia, and the use of antibiotics to treat neutropenia were recorded. Results There was statistically no significant difference in the incidence of FN (0% vs. 1.4%, p = 1), antibiotic use due to neutropenia (0% vs. 2.7%, p = 0.881), estimated lowest mean marginal (EM) platelet (106.56 × 109/L vs. 127.70 × 109/L, p = 0.056) and hemoglobin (110.48 g/L vs. 110.14 g/L, p = 0.906) levels between the two groups. However, when compared with the No‐PP‐group, the white blood cell count in the PP‐group was significantly higher (EM means: 4.95 × 109/L vs. 2.80 × 109/L, p < 0.01), while the incidence of grade III or IV neutropenia was significantly lower (9.1% vs. 68.1%, p < 0.01). Conclusions The administration of a low dose (3 mg) of PEG‐rhG‐CSF within approximately 24 h or up to three days following EP treatment is safe and effective at reducing the risk of neutropenia. These findings bring a more flexible administration interval between PEG‐rhG‐CSF and EP treatment.

show abstract

Optimal use of recombinant granulocyte colony-stimulating factor with chemotherapy for solid tumors

Cited by 10 publications

References 81 publications

Scorpion venom peptide SPVII promotes irradiated cells proliferation and increases the expression of the IL-3 receptor

Scorpion venom peptide SPVII promotes irradiated cells proliferation and increases the expression of the IL-3 receptor

<p>Treating advanced breast cancer with metronomic chemotherapy: what is known, what is new and what is the future?</p>

Safety and efficacy of administering reduced doses of pegylated recombinant human granulocyte‐colony stimulating factors in patients treated with cisplatin and etoposide for small cell carcinoma: A retrospective study

Contact Info

Product

Resources

About